Group 1 - The company plans to invest up to 300 million yuan in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. through a share placement, acquiring up to 63.157895 million new shares at a price of 4.75 yuan per share [1] - After the investment, the company's ownership stake in Haihe Pharmaceutical is expected to be between 5% and 8.09% [1] - Haihe Pharmaceutical focuses on the discovery, development, production, and commercialization of innovative drugs in the oncology field, with three products already launched in China and Japan, and five products in clinical research [1] Group 2 - This capital increase is a strategic financial investment reflecting the company's positive outlook on the long-term development potential of innovative drugs, aiming to ensure stable operations while seeking reasonable financial returns and exploring opportunities in emerging industries [2]